Early-Study safety check on lenalidomide after transplant for myeloma
NCT ID NCT01421927
First seen May 27, 2026 · Last updated Jun 07, 2026 · Updated 4 times
Summary
This early-phase study looked at whether the drug lenalidomide is safe to give after a stem cell transplant for multiple myeloma that has come back. It included 13 adults aged 18 to 65 whose cancer had responded to previous treatment. The goal was to see how many people had serious side effects that forced them to stop taking lenalidomide. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Bordeaux - Hôpital Haut-Lévêque
Pessac, 33600, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.